Judy

Judy Security Launches Next-Generation Control Center, Elevating MSP and MSSP Cybersecurity Management

Retrieved on: 
Tuesday, October 24, 2023
Steve Mautone, Judy, Intelligence, Luigi, Control center, Health, Goliath, Multitenancy, Architecture, Glass, Acquisition, Empowerment, Information Security Group, Control, MSSP, Workflow, Member of the Scottish Parliament, Telemetry, Risk management, Cryptocurrency

DETROIT, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Judy Security, a leading provider of simple and affordable all-in-one cybersecurity for SMBs, today announced Judy Control Center. The new platform offers advanced multi-tenant reporting, analytics and guidance, empowering MSPs and MSSPs with seamless cybersecurity management. Featuring a redesigned user-centric interface, Judy's Control Center simplifies the acquisition of valuable insights for partners and customers without unnecessary complexity, enabling them to enhance security and optimize workflow through detailed threat analysis.

Key Points: 
  • New Platform Adapts to Evolving Business Needs, Empowering Channel Partners to Harness Judy's Intelligence for Enhanced Security Strategies
    DETROIT, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Judy Security , a leading provider of simple and affordable all-in-one cybersecurity for SMBs, today announced Judy Control Center.
  • The new platform offers advanced multi-tenant reporting, analytics and guidance, empowering MSPs and MSSPs with seamless cybersecurity management.
  • Today's announcement lays the foundation for the Judy Control Center with plans for additional enhancements in the coming months.
  • To learn more or schedule a demo of the Judy Control Center visit: https://tinyurl.com/bookjudy .

Piccola Cucina Inc. Acquires Assets of Judy G Foods Inc. in a Strategic Move to Expand Consumer Packaged Offerings to the Gluten Free & Allergen Sensitive Communities

Retrieved on: 
Monday, October 2, 2023
Taste, Food industry, Safeway, Woman, Judy, How I Braved Anu Aunty and Co-Founded a Million Dollar Company, ALTA, Female, Fast-moving consumer goods, Entrepreneurship, Acquisition, Woman-owned business, Health, Allergen, Calgary Co-op, Flour, Management, Dietary supplement, Sobeys

Pina built a business that not only fills a gap in the market but also empowers women in the field of food entrepreneurship.

Key Points: 
  • Pina built a business that not only fills a gap in the market but also empowers women in the field of food entrepreneurship.
  • Judy G Foods Inc., a well-respected business in the specialty food market, has built a stellar reputation for its high-quality, gourmet products over the years.
  • with the addition of the Judy G lines of frozen pizza crust, topped pizzas, and “Moments” vegan superfood desserts.
  • As a Canadian, women owned business we are thrilled Judy G has entrusted us  to continue her legacy.”
    Diverse Product Line: Piccola Cucina offers a wide range of gluten free products.

Israel@75

Retrieved on: 
Friday, March 24, 2023
Spend, Minneapolis Jewish Federation, Music, Painting, Culture, Judy, Multimedia, The Jewish Journal, Family, Time Out (magazine), Nightclub, Interior design, Online shopping, Temple Sinai

LOS ANGELES, March 23, 2023 /PRNewswire/ -- Los Angeles community organizations are coming together for Israel@75, a festival celebrating Israel's diamond anniversary. "Israel is like family - I celebrate her extraordinary successes and grieve when she falters," says event organizer Craig Taubman. "My hope is that these events will open up a conversation about the past, present, and future of a modern-day miracle."

Key Points: 
  • "Israel is like family - I celebrate her extraordinary successes and grieve when she falters," says event organizer Craig Taubman.
  • "My hope is that these events will open up a conversation about the past, present, and future of a modern-day miracle."
  • Opening night is scheduled for April 23rd and will include the debut of the short film Becoming Herzl, featuring Award-winning actor Larry Cedar.
  • For a complete list of event and tickets, visit www.MyIsrael75.org or call PH 213 915 0084
    View original content to download multimedia: https://www.prnewswire.com/news-releases/israel75-301779248.html

City of Hope to Accelerate the Development of New Treatments and Expand Best-In-Class Compassionate Care With a Transformative Gift From the Judy and Bernard Briskin Family Foundation

Retrieved on: 
Wednesday, December 7, 2022
Cancer Treatment Centers of America, Ministry of Research, Innovation and Science, Multiple myeloma, Patient, City, American Home, LOS, Morgan Chu, Alzheimer's disease, Immunotherapy, Partnership, Research, Leukemia, Health, City of Hope, Cancer, Museum, Lacos Land Co v. Arden Group Inc, Translational Genomics Research Institute, Market, Lancaster Museum of Art and History (MOAH), Disease, Family, Judy, Diabetes, Haematopoietic system, House Beautiful, COVID-19, Gelson, Multimedia, CAR, Weeping Angel, COVID-19 vaccine, World War II, California Home + Design, Multiple Myeloma Research Foundation, City of Hope National Medical Center, Organization, Pharmaceutical industry, Hospital, Art, Hope, Architectural Digest

LOS ANGELES, Dec. 7, 2022 /PRNewswire/ -- City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, today announced a generous and transformative gift from the Judy and Bernard Briskin Family Foundation. This latest extraordinary commitment from the Briskin family will support City of Hope's compassionate patient care services with the opening of a new hotel for patients and their families as well as fund translational research, including timely studies that could benefit cancer and Alzheimer's patients.

Key Points: 
  • In recognition of the Briskin family's generous contribution, City of Hope names its new five-story hotel the Judy & Bernard Briskin Hope Village.
  • Judy and the late Bernard Briskin have been transformational supporters of City of Hope for nearly two decades.
  • "The continued support of the Briskin family has left an indelible mark on City of Hope.
  • In recognition of their recent generous contribution, City of Hope is honored to name its new 115,000-square-foot hotel the Judy & Bernard Briskin Hope Village.

City of Hope Researcher Advises Doctors Against Overreliance on a Popular Liquid Biopsy Used to Screen for Colorectal Cancer Recurrence

Retrieved on: 
Tuesday, March 8, 2022
Oncology, Health, Hospitals, Clinical Trials, Research, Science, Clinical research, Cancer, Judy, City of Hope, Lymph, Twitter, Haematopoietic system, JAMA Network Open, Translational Genomics Research Institute, Colorectal cancer, Research, Oncology, X-ray, Liquid biopsy, Cancer Treatment Centers of America, Instagram, Diabetes, CAR, Carcinoembryonic antigen, National Cancer Institute, CT, DNA, Circulating tumor DNA, Neoplasm, NCCN, Radiation, Patient, National Comprehensive Cancer Network, Antigen, Technology, CEA, Immunotherapy, YouTube, Disease, Recurrence, Organization, Liver, LinkedIn, Medical imaging, Pharmaceutical industry, City, Facebook

A liquid biopsy measuring circulating tumor DNA is a novel way to test for residual disease in patients who have recently received curative resection for colon cancer.

Key Points: 
  • A liquid biopsy measuring circulating tumor DNA is a novel way to test for residual disease in patients who have recently received curative resection for colon cancer.
  • City of Hope researchers evaluated 48 study participants who had had their colorectal cancer resected.
  • However, scientists are still working to develop a reliable and sensitive liquid biopsy to detect colorectal cancer recurrence.
  • For more information about City of Hope, follow us on Facebook , Twitter , YouTube , Instagram and LinkedIn .

COUR PHARMACEUTICALS APPOINTS BRIAN C. BOCK AS CHIEF FINANCIAL OFFICER

Retrieved on: 
Monday, February 28, 2022
Lists of diseases, Immune system, Bachelor of Science, CFO, Culture, Company, Northern Arizona University, Multimedia, Lincoln International, University of Arizona, Biotechnology, Judy, Financial management, Autoimmune disease, Immunodeficiency, Degenerative disease, Technology, RBC Capital Markets, Takeda Pharmaceutical Company, History, CEO, Research, Vaccine, Northwestern University, Science

CHICAGO, Feb. 28, 2022 /PRNewswire/ -- COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the appointment of Brian C. Bock as the Company's new Chief Financial Officer (CFO). Mr. Bock will draw on his more than 20 years of financial management experience in life science operations and investment banking to support the Company's long-term growth strategy.  

Key Points: 
  • CHICAGO, Feb. 28, 2022 /PRNewswire/ --COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the appointment of Brian C. Bock as the Company's new Chief Financial Officer (CFO).
  • Mr. Bock will draw on his more than 20 years of financial management experience in life science operations and investment banking to support the Company's long-term growth strategy.
  • While at Exicure, Mr. Bock was engaged in business development activities, raising capital and oversaw the Company's finance and accounting departments, and investor relations.
  • COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.

AaDya Security Lands $3.1M in Venture Funding to Accelerate Expansion in the SMB-Focused Cybersecurity Market

Retrieved on: 
Thursday, January 27, 2022
Headache, Solution, Software as a service, B2B, MSP, Media contacts database, Machine learning, Time, DNS, Knowledge, Chief executive officer, Entrepreneurship, AI, Aadya Bedi, GLOBE, Judy, Member of the Scottish Parliament, General partnership

The funding will support the launch of Judy 3.0, a streamlined version of the company's all-in-one cybersecurity platform, and will allow AaDya to expand its product, sales, and marketing teams to accelerate customer growth and service increasing market demand.

Key Points: 
  • The funding will support the launch of Judy 3.0, a streamlined version of the company's all-in-one cybersecurity platform, and will allow AaDya to expand its product, sales, and marketing teams to accelerate customer growth and service increasing market demand.
  • Companyon Ventures in Boston led the funding round with participation from new investors including Gutbrain Ventures, PBJ Capital, and Gaingels.
  • "We're thrilled to lead this round and support AaDya's expansion into the market through their select MSP partners."
  • Headquartered in Detroit, Michigan, AaDya Security provides smart, simple, effective and affordable cybersecurity software solutions for small and midsize businesses.

COUR Pharmaceuticals Receives FDA Fast Track Designation for CNP-104 for the Treatment of Primary Biliary Cholangitis

Retrieved on: 
Monday, January 10, 2022
CNP, Safety, Lists of diseases, Priority, Judy, Disease, Patient, Immune system, Primary biliary cholangitis, IND, Food, Review, Research, Company, Communication, Technology, Ironwood, FDA, Immunodeficiency, Accelerated approval (FDA), Autoimmunity, PBC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, Vaccine, Pharmaceutical industry, Northwestern University

CHICAGO, Jan. 10, 2022 /PRNewswire/ --COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis.

Key Points: 
  • CHICAGO, Jan. 10, 2022 /PRNewswire/ --COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis.
  • If successful in Phase 2, COUR would seek breakthrough therapy designation in PBC given that current therapies treat only symptoms."
  • Fast Track Designation is an FDA process designed to facilitate the development and review of potential therapies that seek to fill an unmet medical need.
  • COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.

City of Hope Researchers Help Find Improved Treatment Options for Patients With Advanced Colorectal Cancer

Retrieved on: 
Tuesday, December 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Translational Genomics Research Institute, Instagram, Standard of care, City of Hope, National Comprehensive Cancer Network, Population, Heath Robinson (codebreaking machine), Amgen, U.S. News & World Report, Progression-free survival, Colorectal cancer, EGFR, Korea Disease Control and Prevention Agency, Panitumumab, National Cancer Institute, Cancer, Haematopoietic system, Survival, Biomedical Research, Immunotherapy, News, Gastrointestinal cancer, Center, NCI, Large intestine, Patient, Nausea, KRAS, Trifluridine, Oncology, Twitter, YouTube, CAR, Diabetes, Clinical research, Judy, Technology, Diarrhea, Pharmaceutical industry, Hope, Research, The Lancet, City, Facebook

City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer.

Key Points: 
  • City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer.
  • Colorectal cancer is the third most common cancer diagnosed in the United States and the second leading cause of cancer death, according to the Centers for Disease Control and Prevention.
  • Currently, overall response rate for patients with recurrent metastatic colorectal cancer who take approved options, such as trifluridine and regorafenib, ranges from 1-4%, Fakih said.
  • A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report.

Outerbridge Issues Presentation Refuting Comtech’s False and Misleading Claims

Retrieved on: 
Wednesday, December 1, 2021
Professional Services, Finance, Viasat (American company), Kratos Defense & Security Solutions, CEO, Review, Axon Enterprise, PIPE, Technology, Industry, TSR, Engineering, Leadership, Gilat Satellite Networks, ST Engineering, Peer, CMTL, Peer group, ALL, Judy, Motorola Solutions, Annual general meeting, Risk, LLC, Telecommunication, Teledyne Technologies, Board, M&A, Name, NUALS Arts and Literary Annual Meet, Outerbridge, NASDAQ, Elbit Systems, Management

Outerbridge Capital Management, LLC (Outerbridge), a beneficial owner of approximately 4.9% of Comtech Telecommunications Corp.s (NASDAQ: CMTL) (Comtech or the Company) outstanding shares of common stock, today issued an investor presentation refuting the false and misleading claims contained in Comtechs recent public materials.

Key Points: 
  • Outerbridge Capital Management, LLC (Outerbridge), a beneficial owner of approximately 4.9% of Comtech Telecommunications Corp.s (NASDAQ: CMTL) (Comtech or the Company) outstanding shares of common stock, today issued an investor presentation refuting the false and misleading claims contained in Comtechs recent public materials.
  • The presentation highlights the following:
    Change is urgently needed to bring critical relevant experience to the boardroom.
  • Despite Comtechs misleading and false claims of business momentum, the Board has in fact overseen significant shareholder value destruction, is cherry-picking data in its characterization of total shareholder return (TSR), and has made disastrous capital allocation decisions.
  • Outerbridge nominees Wendi Carpenter and Sidney Fuchs are the right choice for Comtechs Board.